VTRS Stock Summary and Trading Ideas (Viatris | NASDAQ:VTRS)

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

Viatris trades on the NASDAQ stock market under the symbol VTRS.

As of November 12, 2026, VTRS stock price declined to $20.90 with 467,477 million shares trading.

VTRS has a beta of 0.32, meaning it tends to be less sensitive to market movements. VTRS has a correlation of 0.02 to the broad based SPY ETF.

VTRS has a market cap of $23.96 billion. This is considered a Large Cap stock.

Last quarter Viatris reported $4 billion in Revenue and $.71 earnings per share. This fell short of revenue expectation by $-37 million and exceeded earnings estimates by $.07.

In the last 3 years, VTRS traded as high as $21.18 and as low as $6.85.

The top ETF exchange traded funds that VTRS belongs to (by Net Assets): VTI, VOO, VB, IVV, VBR.

VTRS has outperformed the market in the last year with a price return of +90.9% while the SPY ETF gained +11.8%. VTRS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +29.1% and +11.3%, respectively, while the SPY returned -1.6% and -2.1%, respectively.

VTRS support price is $20.66 and resistance is $21.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTRS shares will trade within this expected range on the day.